Company / Profit Margin
CUMBERLAND PHARMACEUTICALS INC Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
10.7%
FY2025
5-year range
-15.9% / 10.7%
FY2021-FY2025
Trend
+167.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin returned to growth in FY2025 after 2 years of decline, reaching 10.7%.
Based on SEC 10-K filings.
10.7% in FY2025 with a 5-year CAGR of +19.7%.
Improved from -13.3% to 10.7% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +20.5pp
- 5-Year Change
- +19.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin increased 167.6% year-over-year.
- Peak profit margin was recorded in FY2016.
- Lowest profit margin in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 10.7% | +167.6% |
| FY2024 | -15.9% | -19.8% |
| FY2023 | -13.3% | -36.0% |
| FY2022 | -9.8% | +5.2% |
| FY2021 | -10.3% | -15.4% |
| FY2020 | -8.9% | +13.3% |
| FY2019 | -10.3% | -259.8% |
| FY2018 | -2.9% | -103.5% |
| FY2017 | 81.3% | -79.9% |
| FY2016 | 404.0% | +253.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026